MiStent SES received CE mark approval in the European Union, which has been developed to enhance healing in patients with coronary artery disease.

Micell Technologies chairman and CEO Arthur Benvenuto said: "Patients with cardiovascular disease and their physicians now have access to a new class of drug-eluting stent that allows the drug to remain in the tissue for an extended period — well beyond a rapidly-absorbing polymer.

MiStent SES features proprietary stent coating, which includes crystalline drug (sirolimus) and an absorbable polymer.

The coating is said to provide controlled and sustained release of therapeutic levels of drug as the polymer disperses from the stent into the adjacent tissue, noted Micell.

Micell’s distribution partner Stentys will exclusively supply the stent system across the globe, except in the US, Canada, China, South Korea and Japan.